U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07177911) titled 'Safety and Efficacy Study of CC312 for Moderate to Severe SLE' on Sept. 10.
Brief Summary: This study is a randomized, double-blind, placebo-controlled Phase I clinical trial featuring single and multiple ascending doses. It is designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of CC312 in adult patients with moderate to severe systemic lupus erythematosus (SLE).
Study Start Date: Sept. 11
Study Type: INTERVENTIONAL
Condition:
SLE - Systemic Lupus Erythematosus
Intervention:
DRUG: CC312
Subjects will initially receive a single intravenous dose...